CTOs on the Move

Cytrellis

www.cytrellis.com

 
Cytrellis is a medical technology company dedicated to the development and commercialization of first-in-class aesthetic devices which emphasize safety, efficacy, and improved quality of life for our patients. Cytrellis` first product, the ellacor® System with Micro-Coring™ Technology, is indicated for use by medical professionals for the treatment of moderate to severe wrinkles in the mid to lower face in adults aged 22 years or older with Fitzpatrick skin types I-IV. Ellacor provides aesthetic practitioners with an unprecedented ability to improve age-related changes in skin and to help restore youthful beauty.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Shivkumar Sabesan
Chief Technology Officer Profile

Funding

Cytrellis raised $28.5M on 06/05/2018

Similar Companies

Horschel Brothers Precision

Horschel Brothers Precision is a Springville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Novarix

Novarix is a collaborative medical device development company based near Oxford, UK and Raleigh, North Carolina, USA, delivering innovative new products in the field of venepuncture and cannulation to the worldwide healthcare sector. Novarix are proud to bring to market the IV-eye® – a portable, near infrared (NIR) vein imaging device which demonstrates the company ethos of practicality, simplicity and performance for both healthcare professionals and patients. The product idea came from a nursing perspective and has been developed in consultation with medical professionals in the UK and Denmark and with assistance from the biomedical engineering departments of Oxford University and University College London.

Mastercraft Dental Co of Texas

Mastercraft Dental Co of Texas is a Midlothian, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Conor Medsystems

Conor Medsystems, Inc. develops controlled vascular drug delivery technologies. It has initially focused on the development of drug-eluting stents to treat coronary artery disease. Its stents have been specifically designed for vascular drug delivery, in